VAD方案与BCD方案化疗对多发性骨髓瘤患者血液指标、骨代谢调节因子水平的影响

Effects of VAD and BCD Chemotherapy on Blood Indexes and Bone Metabolism Regulators in Patients with Multiple Myeloma

目的:探讨VAD方案与BCD方案化疗对多发性骨髓瘤(MM)患者血液指标、骨代谢调节因子水平的影响。方法:选择2017年7月-2019年6月于本院治疗的MM患者76例,按随机数字表法将其分为对照组与观察组,各38例。对照组进行VAD方案化疗,观察组进行BCD方案化疗。比较两组治疗前后血液指标、骨代谢调节因子指标及不良反应发生情况。结果:治疗后,观察组β2-微球蛋白(β2-MG)、血清单克隆蛋白(M蛋白)、抗酒石酸酸性磷酸酶及碱性磷酸酶(TRACP-5b)及核因子κB受体活化因子配体(RANKL)均低于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:BCD方案化疗能够改善MM患者血液指标及骨代谢调节因子,效果确切,临床应用安全性较高。

Objective:To investigate the effects of VAD and BCD chemotherapy on blood indexes and bone metabolism regulators in patients with multiple myeloma (MM).Method:A total of 76 MM patients treated in our hospital from July 2017 to June 2019 were selected.They were divided into control group and observation group,38 cases in each group.The control group treated with VAD chemotherapy,and the observation group treated with BCD chemotherapy.Blood indexes,bone metabolism regulators and adverse reactions of the two groups were compared before and after treatment.Result:After treatment,β2-microglobulin (β2-MG),serum monoclonal protein (M protein),anti-tartrate acid phosphatase and alkaline phosphatase (TRACP-5b) and nuclear factors κB receptor activating factor ligand (RANKL) in the observation group were lower than those in the control group (P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion:BCD chemotherapy can improve blood indexes and bone metabolism regulators in patients with MM,with accurate effect and high safety in clinical application.